公开(公告)号：EP1391214A1

公开(公告)日：2004-02-25

申请号：EP02724748.5

申请日：2002-05-09

申请人： Anges MG, Inc.

发明人： MORISHITA, Ryuichi ,  NAKANISHI, Kuniaki ,  KANEDA, Yasufumi ,  KOTANI, Hitoshi

IPC分类号： A61K48/00 ,  A61K38/22 ,  A61P17/02 ,  A61P17/14

CPC分类号： A61K38/1709 ,  A61K38/1825 ,  A61K38/1833 ,  A61K38/1866 ,  A61K48/005

摘要： The present invention relates to a therapeutic preventive agent that includes an angiogenic factor gene (such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and hypoxia inducible factor (HIF) ) as its active ingredient, and the administration of such an agent into the targeted skin diseases-affected area.

摘要翻译： 本发明涉及包含血管生成因子基因（如肝细胞生长因子（HGF），血管内皮生长因子（VEGF）），成纤维细胞生长因子（FGF）和缺氧诱导因子（HIF））的治疗性预防药物 活性成分，以及将这种药剂施用于目标皮肤疾病影响区域。

公开(公告)号：EP3222289A1

公开(公告)日：2017-09-27

申请号：EP15861370.3

申请日：2015-11-20

申请人： AnGes MG, Inc. ,  Osaka University ,  DS Pharma Animal Health Co. Ltd.

发明人： NAKAGAMI, Hironori ,  MORISHITA, Ryuichi ,  KORIYAMA, Hiroshi ,  TOMIOKA, Hideki ,  NAOHARA, Kenji

IPC分类号： A61K39/00 ,  A61K39/29 ,  A61P9/00 ,  A61P9/12

CPC分类号： A61K39/292 ,  A61K39/0008 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/70 ,  C12N7/00 ,  C12N2730/10134

摘要： The present invention provides a combination preparation for inducing a specific immune response to an antigenic peptide, which contains
(I) the antigenic peptide, and
(II) an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide, into which the antigenic peptide has been inserted or added, wherein said antigenic peptide is inserted in a region of amino acid residues 74 - 87 or 130 - 138 of the hepatitis B virus core antigen polypeptide, or added to the N-terminal or C-terminal of the hepatitis B virus core antigen polypeptide, wherein
the antigenic peptide of (I) and the expression vector of (II) are substantially simultaneously administered to a subject.

摘要翻译： 本发明提供了用于诱导针对抗原肽的特异性免疫应答的组合制剂，所述抗原肽包含（I）抗原肽和（II）编码嵌合乙型肝炎病毒核心抗原多肽的表达载体，所述抗原肽具有 被插入或添加，其中所述抗原肽被插入乙型肝炎病毒核心抗原多肽的氨基酸残基74-87或130-138的区域，或被添加到乙型肝炎病毒的N-末端或C-末端 （I）的抗原肽和（II）的表达载体基本上同时施用于受试者的核心抗原多肽。

公开(公告)号：EP2371840A9

公开(公告)日：2012-02-22

申请号：EP09829160.2

申请日：2009-11-27

申请人： AnGes MG, Inc.

发明人： GEMBA, Takefumi ,  TOMIOKA, Hideki ,  SATA, Ryoko ,  TAMURA, Nao ,  MAEDA, Akito ,  KANAMORI, Toshihide ,  SAITO, Yoshimi ,  KOMABA, Shintaro ,  MORISHITA, Ryuichi

IPC分类号： C07K7/08 ,  A61K38/00 ,  A61P9/00 ,  A61P9/10 ,  A61P17/00 ,  A61P17/02 ,  A61P31/04 ,  C07K14/435 ,  C07K14/515

CPC分类号： C07K14/001 ,  A61K38/00 ,  C07K14/515

摘要： Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for the prevention, amelioration or treatment of skin wounds caused by a cut wound, surgical wound, erosion, burn, decubitus,intractable wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease or arteriosclerosis obliteran, and for the prevention, amelioration or treatment of bacterial infection in such skin wounds, and the like.

摘要翻译： 公开了具有优异的血管生成诱导活性和优异的抗菌活性的新型多肽及其医学用途。 新多肽的氨基酸序列显示于SEQ ID NO：1至6中的任何一个中。这些多肽具有诱导血管发生和抗菌活性。 这样的多肽可用于预防，改善或治疗由切伤，手术伤口，侵蚀，烧伤，褥疮，顽固性伤口，皮肤溃疡，腿部溃疡，糖尿病性溃疡，闭塞性动脉疾病或闭塞性动脉硬化症引起的皮肤伤口， 在这种皮肤伤口中预防，改善或治疗细菌感染等。

公开(公告)号：EP1803811B1

公开(公告)日：2011-05-11

申请号：EP05799368.5

申请日：2005-10-20

申请人： AnGes MG, Inc.

发明人： MORISHITA, Ryuichi ,  OGIHARA, Toshio ,  AOKI, Motokuni ,  MIYAKE, Takashi

IPC分类号： C12N15/00 ,  C12N15/09 ,  A61K31/70 ,  A61K48/00 ,  A61P1/04 ,  A61P9/10 ,  A61P11/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P19/02 ,  A61P29/00 ,  A61P31/12 ,  A61P35/00 ,  A61P37/06 ,  A61P37/08

CPC分类号： C12N15/113 ,  A61K48/00 ,  C12N2310/13 ,  C12N2310/3519

摘要： It is intended to provide a drug for preventing, ameliorating or treating vascular restenosis, ischemic diseases, allergic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis or infiltration (cancerous metastasis/infiltration) or cachexia based on the inhibition of a plural number of transcriptional regulators. Namely, a chimeric (double) decoy (a decoy molecule) having a plural number of transcriptional regulator-binding sequences per molecule. Thus, it can inhibit a plural number of transcriptional regulator-inhibiting activities by a single molecule. For example, stenosis in an inosculation site of an artificial vessel is resulted from thickening in the vascular endosporium mainly caused by activated cell proliferation due to an inflammatory reaction in the inosculation site. By simultaneously inhibiting two transcriptional regulators participating in the inflammation and the cell proliferation with the use of the above-described chimeric decoy, therefore, the thickening in the vascular wall can be inhibited.

公开(公告)号：EP2266626A1

公开(公告)日：2010-12-29

申请号：EP09724284.6

申请日：2009-03-27

申请人： AnGes MG, Inc. ,  Medrx Co., Ltd.

发明人： SHINOHARA, Kazuya ,  HAMAMOTO, Hidetoshi ,  KOBAYASHI, Katsunori ,  NAKANO, Tatsuro ,  SAKAGUCHI, Makoto

IPC分类号： A61K48/00 ,  A61K9/06 ,  A61K31/7088 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18 ,  A61P11/06 ,  A61P17/00 ,  A61P19/02 ,  A61P29/00 ,  A61P37/08

CPC分类号： C12N15/113 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/7088 ,  A61K47/06 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18 ,  C12N15/88 ,  C12N2310/13

摘要： The present invention provides an external preparation composition of transcription factor decoy of good skin permeability, the composition comprising a transcription factor decoy dissolved in a fatty acid-based ionic liquid obtained from a fatty acid having 2 to 20 carbon atoms and an organic amine compound having 4 to 12 carbon atoms.

摘要翻译： 本发明提供了良好的皮肤透过性的转录因子诱饵的外用制剂组合物，所述组合物包含在由具有2至20个碳原子的脂肪酸得到的脂肪酸系离子液体和有机胺化合物具有溶解转录因子诱饵 4至12个碳原子。

公开(公告)号：EP1739425B1

公开(公告)日：2009-09-09

申请号：EP05728425.9

申请日：2005-03-30

申请人： AnGes MG, Inc.

发明人： SATO, Naoyuki ,  OKOCHI, Masayasu ,  TANIYAMA, Yoshiaki ,  OGIHARA, Toshio ,  MORISHITA, Ryuichi

IPC分类号： G01N33/50 ,  G01N33/15 ,  G01N33/68

CPC分类号： G01N33/6896 ,  G01N2333/4709 ,  G01N2500/00 ,  G01N2500/04 ,  G01N2800/2821 ,  G01N2800/2835

摘要： It is intended to provide a method of identifying a candidate for a drug which comprises measuring the concentration of a soluble peptide, oligopeptide, polypeptide or protein in an equilibrated state in a solvent in the presence of a test compound so that the peptide, oligopeptide, polypeptide or protein can be eliminated from a fibril or an aggregate. It is also intended to provide an elution promoter for eliminating a peptide, an oligopeptide, a polypeptide or a protein from a fibril or an aggregate which comprises a compound obtained by the above identification method as the active ingredient.

公开(公告)号：EP1642591A4

公开(公告)日：2009-08-19

申请号：EP04747306

申请日：2004-07-09

申请人： ANGES MG INC

发明人： MORISHITA RYUICHI ,  AOKI MOTOKUNI ,  OGIHARA TOSHIO ,  KAWASAKI TOMIO ,  MAKINO HIROFUMI ,  SHISHIKURA TAKASHI ,  KOYANAGI AKIHIRO

IPC分类号： A61K45/00 ,  A61K9/00 ,  A61K9/08 ,  A61K9/12 ,  A61K9/127 ,  A61K9/14 ,  A61K9/72 ,  A61K31/7088 ,  A61K31/711 ,  A61K35/76 ,  A61K38/17 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/30 ,  A61K48/00 ,  A61P9/00 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P29/00 ,  A61P31/10 ,  A61P35/00 ,  A61P37/08

CPC分类号： A61K9/0078 ,  A61K9/0075 ,  A61K9/008 ,  A61K31/711 ,  A61K38/1709 ,  A61K45/06

摘要： A medicinal composition for treating and preventing diseases, disorders and/or conditions of airway inflammation, airway narrowing or nasal cavity inflammation caused by the expression of a gene regulated by NF-kappaB which contains an NF-kappaB decoy and a pharmaceutically acceptable carrier. The above diseases may be asthma, COPD or rhinitis. Moreover, the above diseases may be diseases caused by abnormality in eosinophils (for example, asthma, rhinitis and COPD). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome and so on.

公开(公告)号：EP1837035A4

公开(公告)日：2009-08-05

申请号：EP06700849

申请日：2006-01-12

申请人： ANGES MG INC

发明人： OTSU KUNIMIKI ,  SAITO TETSU ,  GEMBA TAKEFUMI

IPC分类号： A61K45/00 ,  A61K9/14 ,  A61K9/72 ,  A61K31/7088 ,  A61K31/713 ,  A61K48/00 ,  A61P11/00 ,  C12N15/09

CPC分类号： A61K9/0073 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/008 ,  A61K31/7088 ,  A61K31/713 ,  C12N15/113 ,  C12N2310/13

公开(公告)号：EP1470826B1

公开(公告)日：2009-01-28

申请号：EP02711288.7

申请日：2002-02-01

申请人： AnGes MG, Inc.

发明人： MORISHITA, Ryuichi, c/o AnGes MG, Inc. ,  AOKI, Motokuni, c/o AnGes MG, Inc. ,  OGIHARA, Toshio, c/o AnGes MG, Inc. ,  KAWASAKI, Tomio, c/o AnGes MG, Inc.

IPC分类号： A61K48/00 ,  A61K31/711 ,  A61P9/10 ,  A61K9/08 ,  A61P29/00 ,  A61P11/06 ,  A61P17/00 ,  A61P13/12

CPC分类号： A61K9/127 ,  A61K31/711 ,  A61K38/08 ,  A61K38/1709 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  A61K48/0008 ,  A61K48/005 ,  C12N15/113 ,  C12N15/86 ,  C12N2310/13 ,  C12N2710/10343 ,  C12N2740/13043

摘要： Pharmaceutical compositions for treating and preventing diseases caused by the expression of a gene under the regulation by NF - ĸB or ets which contain at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy as described above involves a decoy of NF - ĸB, a decoy of ets and a chimeric decoy of a decoy of NF - ĸB and ets. The diseases as described above include brain aneurysm, caner, Marfan’s syndrome, aortic dissection, postangioplastic reconstriction, rheumatoid arthritis, asthma, atopic dermatitis, nephritis, renal insufficiency and plaque rapture. The pharmaceutically acceptable carrier as described above may be a hydrophilic polymer.

公开(公告)号：EP1142590B1

公开(公告)日：2008-10-01

申请号：EP00971697.8

申请日：2000-10-26

申请人： AnGes MG, Inc.

发明人： MORISHITA, Ryuichi ,  OGIHARA, Toshio

IPC分类号： A61K48/00 ,  A61K38/22 ,  A61K9/127 ,  A61P9/10 ,  A61P3/10

CPC分类号： A61K38/1833 ,  A61K9/127 ,  A61K9/1272 ,  A61K48/00 ,  A61K48/0016 ,  A61K48/0025 ,  A61K48/0075 ,  C07K14/4753 ,  C12N7/00 ,  C12N2760/18843

摘要： Administration of an HGF (hepatocyte growth factor) gene to a diabetic ischemic site achieves effect of promoting the angiogenesis of the ischemic site with the depression caused by diabetes and thus causing recovery from an ischemic disease.